ALNY

Business Context and Reporting Period

Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Alnylam is a global commercial-stage biopharmaceutical company developing RNAi therapeutics. As of March 31, 2025, the company has six marketed products (four commercialized directly: AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO; two by collaborators: Leqvio, Qfitlia) and a pipeline of over 20 clinical programs. The company is executing its "Alnylam P 5 x25" strategy to become a top-tier biotech by the end of 2025.

Key Financial Metrics

Note: Cash, Cash Equivalents & Marketable Securities calculated as sum of Cash ($1,019,654), Marketable Debt Securities ($1,605,368), and Marketable Equity Securities ($7,200) as of March 31, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 20% year-over-year (YoY), driven primarily by a 28% increase in net product revenues. AMVUTTRA revenues grew 59% to $310.0 million, while ONPATTRO revenues declined 29% to $49.5 million due to patient switching to AMVUTTRA.
• Operating Profitability: The company reported an operating income of $18.1 million in Q1 2025, a significant improvement from an operating loss of $43.4 million in Q1 2024. This shift was driven by revenue growth outpacing expense increases.
• Collaboration Revenue Volatility: Net revenues from collaborations decreased 16% YoY to $99.2 million. This was primarily due to the recognition of a $65.0 million milestone payment from Roche in Q1 2024 (not repeated in Q1 2025), partially offset by increased revenue from Regeneron and a $30.0 million payment from Vir Biotechnology.
• Other Expense: Total other expense increased significantly to $59.7 million (from $20.2 million), largely due to a $58.9 million loss on the change in fair value of the development derivative liability, driven by the regulatory approval of AMVUTTRA for ATTR-CM.

Guidance, Outlook, and Risks

• Strategic Outlook: Management aims to achieve sustainable operating profitability by the end of 2025. The company expects collaboration revenues to increase in 2025, driven by the Roche collaboration, and royalty revenues to grow due to Leqvio and Qfitlia sales.
• Key Developments:
  • AMVUTTRA: Received FDA approval in March 2025 for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Regulatory reviews for this indication are ongoing in Europe (EMA) and Japan (PMDA).
  • Pipeline: Positive Phase 1 results for nucresiran (ATTR-CM) and mivelsiran (Alzheimer's). Phase 3 trials for nucresiran (TRITON-CM) expected to initiate in H1 2025.
  • Collaborations: Regeneron opted out of co-development of mivelsiran in May 2024; Alnylam now holds full global rights and funding responsibility.
• Liquidity: The company believes its cash, cash equivalents, and marketable securities ($2.63 billion) are sufficient to fund operations for at least the next 12 months.
• Risks & Contingencies:
  • Legal Proceedings: Ongoing patent infringement litigation against Pfizer/BioNTech and Moderna regarding mRNA vaccine lipids. A court order in April 2025 narrowed Alnylam's patent claims, potentially placing Pfizer's product outside coverage. A trial against Pfizer is set for July 7, 2025.
  • Regulatory: Risk of delays or rejections for expanded indications (e.g., AMVUTTRA ATTR-CM outside the U.S.).
  • Convertible Notes: $1.04 billion in 1% Convertible Senior Notes due 2027. Liquidity risks exist if the company cannot settle conversions in cash or refinance debt.

Investor Verification Checklist

• AMVUTTRA ATTR-CM Commercialization: Verify the timeline and success of the commercial launch for the newly approved cardiomyopathy indication in the U.S. and potential approval timelines in Europe and Japan.
• Patent Litigation Status: Monitor the outcome of the Pfizer/BioNTech trial scheduled for July 2025 and the Federal Circuit ruling expected in Q4 2025 regarding the Moderna appeal, as these impact potential royalty revenues and IP protection.
• Operating Profitability Trajectory: Assess whether the Q1 operating income is sustainable or if it was aided by one-time factors, given the company's goal of profitability by end of 2025.
• Development Derivative Liability: Review the valuation assumptions for the Blackstone Life Sciences derivative liability, as changes in fair value significantly impact non-GAAP and GAAP earnings.
• Collaboration Milestones: Track upcoming milestones in the Roche (zilebesiran) and Regeneron collaborations, which are critical drivers of future non-product revenue.